Limb Lengthening Expert Dr. Dror Paley Opens First Clinic in Middle East at UAE’s Burjeel Medical City
10.1.2023 13:57:00 EET | Business Wire | Press release
As part of its ongoing efforts to focus on complex care and pediatric sub-specialties, Burjeel Holdings, one of the leading private healthcare services providers in the MENA region, in collaboration with renowned orthopedic surgeon Dr. Dror Paley, has launched a clinic in the UAE. The Paley Middle East Clinic, located at Burjeel Medical City (BMC) in Abu Dhabi, aims to become a hub for complex procedures in the region by providing world-class specialized orthopedic care. It is the first clinic in the Middle East and Asia by Dr. Paley, who has performed around 20,000 limb-lengthening and reconstruction-related procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005563/en/
Dr. Dror Paley and his team at Paley Middle East Clinic in Burjeel Medical City with Dr. Shamsheer-Vayalil, Founder and Chairman, Burjeel Holdings, and other senior management officials. (Photo: AETOSWire)
Dr. Paley is internationally recognized for his expertise in limb lengthening, deformity reconstruction, and joint preservation of children and adults. The clinic at BMC offers diagnosis and treatment of special orthopedic conditions, including congenital limb deformities, post-traumatic limb conditions, bone healing problems, bone defects, skeletal dysplasia, metabolic disorders, foot deformities, and peripheral nerve disorders.
BMC, one of the leading quaternary care facilities in the UAE, expects the clinic, supported by a comprehensive rehabilitation department, to serve as a beacon for orthopedic surgical excellence and innovation.
“I am delighted to start my innings in the UAE with BMC. Together we aim to transform the UAE into a hub for limb lengthening and deformity correction, attracting patients from across the globe for cutting-edge treatments,” said Dr. Paley.
Welcoming Dr. Paley, Mr. John Sunil, CEO, Burjeel Holdings, said, “The collaboration is yet another important step in the Group’s pursuit of delivering healthcare excellence and improving patient outcomes. We are constantly investing in and establishing new partnerships to identify cutting-edge medical technologies and innovations that can help us deliver complex care to the people. Dr. Paley’s expertise will help the people avail of almost every aspect of orthopedic and neurosurgical care, making the UAE a sought-after hub for such services.”
About Burjeel Medical City
Burjeel Medical City is a 400-bed multi-specialty hospital and quaternary care center located in Abu Dhabi, UAE. It offers high-quality specialized treatment and complex care in over 40 adult and pediatric specialties, aided by state-of-the-art medical technology and an international team of experts.
Find more information at https://www.burjeelmedicalcity.com/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005563/en/
Contact information
M. Unnikrishnan
krish@burjeelholdings.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
Klarna Submits Application for U.S. Banking License6.7.2026 15:30:00 EEST | Press release
Klarna (NYSE: KLAR), the global digital bank and flexible payments provider, today announced it has submitted applications to the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation (FDIC) to establish Klarna Bank USA, a proposed Utah-chartered industrial bank. Klarna has operated as a licensed bank in Europe since 2017 and serves U.S. customers through valued partner banks. Since 2019, Klarna has provided Americans with access to over $91.3 billion in responsible credit, saving them more than $5.1 billion in interest compared to revolving credit card debt. Today, 30 million Americans use Klarna each year, and hundreds of thousands of merchants rely on Klarna to grow their businesses. "Banking is built on trust," said Sebastian Siemiatkowski, co-founder and CEO of Klarna. "We've seen firsthand the appetite for a fairer, more transparent approach in the U.S., and our own banking license is the natural next step, giving customers tools to borrow respon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom